ARTHEx Biotech’s website
4 known investors
Arthex Biotech develops an investigational anti-miR therapeutic targeting an upregulated miRNA for the treatment of myotonic dystrophy, aiming to address the root cause of the disease. Its lead program uses an oligonucleotide conjugated to a fatty acid to improve delivery to muscle tissue at low active doses.
Investors · 4
Frequently asked questions
- What does ARTHEx Biotech’s website do?
- Arthex Biotech develops an investigational anti-miR therapeutic targeting an upregulated miRNA for the treatment of myotonic dystrophy, aiming to address the root cause of the disease. Its lead program uses an oligonucleotide conjugated to a fatty acid to improve delivery to muscle tissue at low active doses.
- Who are ARTHEx Biotech’s website's investors?
- ARTHEx Biotech’s website's investors include AdBio partners, Invivo Capital Partners, Columbus Venture Partners, Sound Bioventures.